Depression - Articles - Page 11

Research Update

Why Do So Many Pediatric Antidepressant Research Trials “Fail”?

April 1, 2023

Pavan Madan, MD. Dr. Madan has no financial relationships with companies related to this material.

Placebo response rates in antidepressant trials tend to run high, making it difficult to know whether an active medication has truly beneficial effect. This research update unpacks possible reasons for this phenomenon that give you insight into how to treat your patients using a rational multimodal approach.

Research Update

Stimulant Treatment Effect on Anxiety in ADHD

April 1, 2023

Gaurav Mishra, MD

Gaurav Mishra, MD. Dr. Mishra has no financial relationships with companies related to this material.

Are stimulant medication likely to exacerbate anxiety in ADHD kids? It’s reasonable concern, especially since mood symptoms can be worse with withdrawal and heart rate goes up in some kids on stimulants. This study gives nuanced insight into the degree to which stimulants impact anxiety in ADHD kids, for better and worse.

Expert Q&A

Addressing Suicidality in Autistic Children and Teens

April 1, 2023

Paul Lipkin, MD

Paul Lipkin, MD.

Neurodevelopmental and developmental behavioral pediatrician. Director, Medical Outpatient Services, Kennedy Krieger Institute, Baltimore, MD.

Dr. Lipkin has served as an advisor for EarliTec and Sarepta Diagnostics. Relevant financial relationships listed for the author have been mitigated.

Autistic kids and teens can become despondent or suicidal. When this happens, we need to take it as seriously as with anyone else. We interviewed Dr. Paul Lipkin who has truly useful tips to help us modify our assessment to communicate effectively back and forth to address the problem.

Expert Q&A

Management of Chronic Pain

April 1, 2023

Lewei (Allison) Lin, MD, MS

Lewei (Allison) Lin, MD, MS. Associate professor, Department of Psychiatry, University of Michigan Medical School; research scientist, Center for Clinical Management Research, VA Ann Arbor Healthcare System. Ann Arbor, MA.

Dr. Lin has served as a consultant for the National Committee for Quality Assurance via a grant from Alkermes. Relevant financial relationships listed for the author have been mitigated.

Patients with psychiatric conditions are more likely than other patients to experience chronic pain and to receive opioid prescriptions. Dr. Lin shares her holistic approaches to pain management that incorporate psychosocial, psychotherapeutic, and psychopharmacologic treatments.

Expert Q&A

Substance-Induced Depression: Diagnosis and Treatment

April 1, 2023

Bryan K. Tolliver, MD, PhD

Bryan K. Tolliver, MD, PhD

Associate professor, Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina. Charleston, SC.

Dr. Tolliver has no financial relationships with companies related to this material.

“When tailoring medication choice, a careful history can guide you. If I’m treating a patient who drinks excessively at night to sleep or who struggles with insomnia when they try to stop drinking, I’ll start with a sedating antidepressant like mirtazapine. That’s not an evidence-based decision, it’s a clinical decision that I think can be helpful.”

Dr. Tolliver gives us a framework to understand the relation between depression, substance use, and substance-induced mood disorders.

Expert Q&A

Herbal Therapies for Depression

March 8, 2023

Scott Mendelson, MD, PhD

Scott Mendelson, MD, PhD.

Recently retired after 25 years of practicing inpatient and outpatient psychiatry in community and VA hospitals. He is the author of several psychiatric textbooks including Herbal Treatment of Major Depression (CRC Press, 2019) and Herbal Treatment of Anxiety (CRC Press, 2022).

Dr. Mendelson has no financial relationships with companies related to this material.

Scott Mendelson shows us how to use the top 3 herbal therapies for depression--namely, St. John’s wort, curcumin, and saffron.

Ketamine Comes Home

February 26, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Online clinics delivered at-home ketamine throughout the pandemic, and we’re just becoming aware of the consequences.

Expert Q&A

Prolonged Grief Disorder

January 30, 2023

M. Katherine Shear, MD

M. Katherine Shear, MD

Marion E. Kenworthy Professor of Psychiatry at Columbia School of Social Work and Vagelos College of Physicians and Surgeons, New York, NY.

Dr. Shear has no financial relationships with companies related to this material.

Prolonged grief disorder is the new edition in DSM-5-TR. Katherine Shear explains how it differs from depression and PTSD and outlines a treatment approach.

Management of Depression and Neurocognitive Impairment in Patients With HIV

January 15, 2023

Victoria Hendrick, MD. and Prabhjot Gill

Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications.

EXPERT Q&A

Psychiatric Issues in Organ Transplantation

January 2, 2023

Paula C. Zimbrean, MD, FAPA, FACLP

Paula C. Zimbrean, MD, FAPA, FACLP

Associate professor of psychiatry and surgery (transplant), Yale University School of Medicine; Chair, Transplant Psychiatry Special Interest Group, Academy of Consultation Psychiatry. New Haven, CT.

Dr. Zimbrean has consulted for Ultragenyx and Vivet Therapeutics, and has consulted and advised for Alexion. Relevant financial relationships listed for the author have been mitigated.

Growing numbers of patients receive organ transplants every year. This Q&A reviews the unique considerations that arise when these patients require psychiatric care.